Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

83.15 +0.01 (+0.01%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction ↗

September 02, 2025

Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy ↗

August 21, 2025

Via Stocktwits

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

An Overview of Ionis Pharmaceuticals's Earnings ↗

July 29, 2025

Via Benzinga

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. ↗

September 02, 2025

Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo.

Via Investor's Business Daily

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup ↗

August 30, 2025

IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern.

Via Chartmill

What's Going On With Takeda Stock On Friday? ↗

August 22, 2025

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock ↗

August 22, 2025

Via Benzinga

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock ↗

August 21, 2025

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

Via Benzinga

Ionis (IONS) Q2 Revenue Soars 101% ↗

July 31, 2025

Via The Motley Fool

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

July 31, 2025

Via Benzinga

Ionis (IONS) Q2 2025 Earnings Call Transcript ↗

July 30, 2025

Via The Motley Fool

Topics Earnings

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug ↗

July 30, 2025

Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations.

Via Benzinga

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching ↗

July 18, 2025

IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders.

Via Chartmill

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

July 01, 2025

Via Benzinga

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗

July 01, 2025

Via Benzinga

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗

June 25, 2025

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Via Benzinga

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Analyst Expectations For Ionis Pharmaceuticals's Future ↗

June 12, 2025

Via Benzinga

Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts ↗

May 20, 2025

Via Benzinga

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts ↗

May 01, 2025

Via Benzinga

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge ↗

April 30, 2025

Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.

Via Benzinga

Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' ↗

April 07, 2025

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.

Via Benzinga

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts ↗

March 31, 2025

Via Benzinga

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today